Show simple item record

Scientific and clinical aspects of the use of cidofovir in recurrent respiratory papillomatosis.

dc.contributor.authorDonne, A J
dc.contributor.authorRothera, M P
dc.contributor.authorHomer, Jarrod J
dc.date.accessioned2009-05-12T18:08:58Z
dc.date.available2009-05-12T18:08:58Z
dc.date.issued2008-07
dc.identifier.citationScientific and clinical aspects of the use of cidofovir in recurrent respiratory papillomatosis. 2008, 72 (7):939-44 Int. J. Pediatr. Otorhinolaryngol.en
dc.identifier.issn0165-5876
dc.identifier.pmid18502519
dc.identifier.doi10.1016/j.ijporl.2008.04.003
dc.identifier.urihttp://hdl.handle.net/10541/67987
dc.description.abstractOBJECTIVE: Cidofovir is the most contemporary adjuvant treatment for recurrent respiratory papillomatosis (RRP) and its use is increasing. Cidofovir is potentially harmful. Otolaryngologists should understand the science of cidofovir and review the current published data on the effects of this therapy. METHOD: Pubmed was searched using the terms cidofovir and papillomatosis. Comparisons were made between published articles. RESULTS: Thirteen articles were identified between 1998 and 2006, representing the treatment of 142 patients. Cidofovir did result in a significant improvement of papillomatous lesions in the majority (60%) of patients despite the use of different regimes of cidofovir administration. There was no unifying protocol in use. A partial response was demonstrated in 29% of patients. 7.5% had no response however, an additional 3.5% patients were lost to follow-up. No malignant change was reported. CONCLUSION: Cidofovir does appear to be effective in improving the outcome of patients with RRP. There are no reports of malignant transformation despite concerns raised by toxicology studies.
dc.language.isoenen
dc.subjectCancer Recurrenceen
dc.subjectThoracic Canceren
dc.subjectCidofoviren
dc.subject.meshAntiviral Agents
dc.subject.meshCytosine
dc.subject.meshHumans
dc.subject.meshNeoplasm Recurrence, Local
dc.subject.meshPapilloma
dc.subject.meshPapillomavirus Infections
dc.subject.meshPhosphonic Acids
dc.subject.meshRespiratory Tract Neoplasms
dc.titleScientific and clinical aspects of the use of cidofovir in recurrent respiratory papillomatosis.en
dc.typeArticleen
dc.contributor.departmentUniversity Department of Otolaryngology and Head and Neck Surgery, Manchester Royal Infirmary, UK. ajdonne@doctors.org.uken
dc.identifier.journalInternational Journal of Pediatric Otorhinolaryngologyen
html.description.abstractOBJECTIVE: Cidofovir is the most contemporary adjuvant treatment for recurrent respiratory papillomatosis (RRP) and its use is increasing. Cidofovir is potentially harmful. Otolaryngologists should understand the science of cidofovir and review the current published data on the effects of this therapy. METHOD: Pubmed was searched using the terms cidofovir and papillomatosis. Comparisons were made between published articles. RESULTS: Thirteen articles were identified between 1998 and 2006, representing the treatment of 142 patients. Cidofovir did result in a significant improvement of papillomatous lesions in the majority (60%) of patients despite the use of different regimes of cidofovir administration. There was no unifying protocol in use. A partial response was demonstrated in 29% of patients. 7.5% had no response however, an additional 3.5% patients were lost to follow-up. No malignant change was reported. CONCLUSION: Cidofovir does appear to be effective in improving the outcome of patients with RRP. There are no reports of malignant transformation despite concerns raised by toxicology studies.


Files in this item

This item appears in the following Collection(s)

Show simple item record